1
|
Ravel C, Kah O. [Endocrine disrupters: Towards an unsatisfying regulation]. Presse Med 2018; 47:943-949. [PMID: 30217365 DOI: 10.1016/j.lpm.2018.08.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/27/2017] [Revised: 05/17/2018] [Accepted: 08/07/2018] [Indexed: 10/28/2022] Open
Abstract
Endocrine disruptors commonly make the headlines of newscasts and magazines, which is not without generating questions, even anxieties, with the general public. In a recent survey, 90% of French people considered it desirable to set up regulations concerning endocrine disruptors. However, under pressure from the lobbies of the chemical industry, and also due to scientific conflicts, the European Union is slow to legislate and has even been condemned before the European Court for failing to fulfill its obligations. This article does not intend to be exhaustive on the issue of endocrine disrupters, but rather to give the reader a certain number of keys enabling him to understand why national or European regulators are slow to establish specific regulation.
Collapse
Affiliation(s)
- Célia Ravel
- Université de Rennes 1, institut de recherche en santé, environnement et travail (Inserm U1085), 9, avenue Professeur-Léon-Bernard, 35000 Rennes, France; CHU de Rennes, hôpital Sud, laboratoire de biologie de la reproduction, CECOS, 16, boulevard de Bulgarie, 35203 Rennes cedex 2, France.
| | - Olivier Kah
- Université de Rennes 1, institut de recherche en santé, environnement et travail (Inserm U1085), 9, avenue Professeur-Léon-Bernard, 35000 Rennes, France.
| |
Collapse
|
2
|
Ponti G, Rodriguez-Gomez A, Farinetti A, Marraudino M, Filice F, Foglio B, Sciacca G, Panzica GC, Gotti S. Early postnatal genistein administration permanently affects nitrergic and vasopressinergic systems in a sex-specific way. Neuroscience 2017; 346:203-215. [PMID: 28131623 DOI: 10.1016/j.neuroscience.2017.01.024] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/10/2016] [Revised: 01/09/2017] [Accepted: 01/12/2017] [Indexed: 12/01/2022]
Abstract
Genistein (GEN) is a natural xenoestrogen (isoflavonoid) that may interfere with the development of estrogen-sensitive neural circuits. Due to the large and increasing use of soy-based formulas for babies (characterized by a high content of GEN), there are some concerns that this could result in an impairment of some estrogen-sensitive neural circuits and behaviors. In a previous study, we demonstrated that its oral administration to female mice during late pregnancy and early lactation induced a significant decrease of nitric oxide synthase-positive cells in the amygdala of their male offspring. In the present study, we have used a different experimental protocol mimicking, in mice, the direct precocious exposure to GEN. Mice pups of both sexes were fed either with oil, estradiol or GEN from birth to postnatal day 8. Nitric oxide synthase and vasopressin neural systems were analyzed in adult mice. Interestingly, we observed that GEN effect was time specific (when compared to our previous study), sex specific, and not always comparable to the effects of estradiol. This last observation suggests that GEN may act through different intracellular pathways. Present results indicate that the effect of natural xenoestrogens on the development of the brain may be highly variable: a plethora of neuronal circuits may be affected depending on sex, time of exposure, intracellular pathway involved, and target cells. This raises concern on the possible long-term effects of the use of soy-based formulas for babies, which may be currently underestimated.
Collapse
Affiliation(s)
- G Ponti
- Department of Veterinary Sciences, Largo Braccini 2, 10095 Grugliasco (TO), University of Torino, Torino, Italy; Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole, 10 - 10043 Orbassano (TO), Torino, Italy.
| | - A Rodriguez-Gomez
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole, 10 - 10043 Orbassano (TO), Torino, Italy; Laboratory of Neuroendocrinology, Department of Neuroscience, Via Cherasco 15, 10126-University of Torino, Torino, Italy
| | - A Farinetti
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole, 10 - 10043 Orbassano (TO), Torino, Italy; Laboratory of Neuroendocrinology, Department of Neuroscience, Via Cherasco 15, 10126-University of Torino, Torino, Italy
| | - M Marraudino
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole, 10 - 10043 Orbassano (TO), Torino, Italy; Laboratory of Neuroendocrinology, Department of Neuroscience, Via Cherasco 15, 10126-University of Torino, Torino, Italy
| | - F Filice
- Laboratory of Neuroendocrinology, Department of Neuroscience, Via Cherasco 15, 10126-University of Torino, Torino, Italy
| | - B Foglio
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole, 10 - 10043 Orbassano (TO), Torino, Italy; Laboratory of Neuroendocrinology, Department of Neuroscience, Via Cherasco 15, 10126-University of Torino, Torino, Italy
| | - G Sciacca
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole, 10 - 10043 Orbassano (TO), Torino, Italy; Laboratory of Neuroendocrinology, Department of Neuroscience, Via Cherasco 15, 10126-University of Torino, Torino, Italy
| | - G C Panzica
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole, 10 - 10043 Orbassano (TO), Torino, Italy; Laboratory of Neuroendocrinology, Department of Neuroscience, Via Cherasco 15, 10126-University of Torino, Torino, Italy
| | - S Gotti
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Regione Gonzole, 10 - 10043 Orbassano (TO), Torino, Italy; Laboratory of Neuroendocrinology, Department of Neuroscience, Via Cherasco 15, 10126-University of Torino, Torino, Italy
| |
Collapse
|
3
|
Slama R, Bourguignon JP, Demeneix B, Ivell R, Panzica G, Kortenkamp A, Zoeller RT. Scientific Issues Relevant to Setting Regulatory Criteria to Identify Endocrine-Disrupting Substances in the European Union. Environ Health Perspect 2016; 124:1497-1503. [PMID: 27108591 PMCID: PMC5047779 DOI: 10.1289/ehp217] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/14/2015] [Revised: 02/17/2016] [Accepted: 04/05/2016] [Indexed: 05/13/2023]
Abstract
BACKGROUND Endocrine disruptors (EDs) are defined by the World Health Organization (WHO) as exogenous compounds or mixtures that alter function(s) of the endocrine system and consequently cause adverse effects in an intact organism, or its progeny, or (sub)populations. European regulations on pesticides, biocides, cosmetics, and industrial chemicals require the European Commission to establish scientific criteria to define EDs. OBJECTIVES We address the scientific relevance of four options for the identification of EDs proposed by the European Commission. DISCUSSION Option 1, which does not define EDs and leads to using interim criteria unrelated to the WHO definition of EDs, is not relevant. Options 2 and 3 rely on the WHO definition of EDs, which is widely accepted by the scientific community, with option 3 introducing additional categories based on the strength of evidence (suspected EDs and endocrine-active substances). Option 4 adds potency to the WHO definition, as a decision criterion. We argue that potency is dependent on the adverse effect considered and is scientifically ambiguous, and note that potency is not used as a criterion to define other particularly hazardous substances such as carcinogens and reproductive toxicants. The use of potency requires a context that goes beyond hazard identification and corresponds to risk characterization, in which potency (or, more relevantly, the dose-response function) is combined with exposure levels. CONCLUSIONS There is scientific agreement regarding the adequacy of the WHO definition of EDs. The potency concept is not relevant to the identification of particularly serious hazards such as EDs. As is common practice for carcinogens, mutagens, and reproductive toxicants, a multi-level classification of ED based on the WHO definition, and not considering potency, would be relevant (corresponding to option 3 proposed by the European Commission). CITATION Slama R, Bourguignon JP, Demeneix B, Ivell R, Panzica G, Kortenkamp A, Zoeller RT. 2016. Scientific issues relevant to setting regulatory criteria to identify endocrine disrupting substances in the European Union. Environ Health Perspect 124:1497-1503; http://dx.doi.org/10.1289/EHP217.
Collapse
Affiliation(s)
- Rémy Slama
- Team of Environmental Epidemiology, IAB (Institute of Advanced Biosciences), Inserm, CNRS, University Grenoble-Alpes, IAB joint research center, Grenoble (La Tronche), France
| | - Jean-Pierre Bourguignon
- Pediatric Endocrinology, CHU Liège and Neuroendocrinology Unit, GIGA Neurosciences, University of Liège, Belgium
| | - Barbara Demeneix
- Department RDDM, Muséum National d’Histoire Naturelle, UMR CNRS/MNHN 7221, Paris, France
| | - Richard Ivell
- School of Biosciences, and
- School of Veterinary Medicine and Science, University of Nottingham, Nottingham, United Kingdom
| | - Giancarlo Panzica
- Department of Neuroscience, University of Torino, Turin, Italy
- Neuroscience Institute Cavalieri Ottolenghi (NICO), Orbassano, Italy
| | - Andreas Kortenkamp
- Institute of Environment, Health and Societies, Brunel University London, Uxbridge, United Kingdom
| | - R. Thomas Zoeller
- Department of Biology, University of Massachusetts, Amherst, Massachusetts, USA
| |
Collapse
|